CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CG Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$59.96+0.11 (+0.18%)
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
CG Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Commercial and Development Revenue | $1.15M | $1.07M | $1.73M | $1.51M | $0 | $0 | $0 | $0 | 99.1% | – |
| License and Collaboration Revenue | $10.00K | $14.00K | $596.00K | $158.00K | $0 | $52.00K | $456.00K | $43.00K | 0.9% | – |
By region
From the segment and revenue-disaggregation notes of CG Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.